ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

Das Universitätsklinikum Heidelberg in Deutschland investiert in das vierte Strahlentherapiegerät von Accuray, das Radixact®-System, um die Versorgung von Krebspatienten zu verbessern

https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2024-financial-results-302222702.html

AH +32,86% ...

Vermutlich haben die Börsianer die Zahlen morgen schon wieder vergessen

Shortsqueeze heute?

Zuckt in die richtige Richtung

💡

https://www.prnewswire.com/news-releases/accuray-and-truenorth-medical-physics-sign-agreement-to-provide-radiation-oncology-support-intended-to-advance-cancer-care-for-more-patients-302176452.html

https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-accuray-precision-treatment-planning-system-by-chinas-national-medical-products-administration-302170420.html

https://finance.yahoo.com/news/accuray-inc-aray-faces-challenges-215957267.html

https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2024-third-quarter-financial-results-302133588.html

https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html

https://www.nasdaq.com/articles/three-reasons-to-retain-accuray-aray-stock-in-your-portfolio

Roth/MKM sets $9 stock target on Accuray, bullish on market expansion https://m.uk.investing.com/news/stock-market-news/rothmkm-sets-9-stock-target-on-accuray-bullish-on-market-expansion-93CH-3335248

Accuray GAAP EPS of -$0.10 misses by $0.05, revenue of $107.2M beats by $0.53M https://seekingalpha.com/news/4060915-accuray-gaap-eps-of-0_10-misses-0_05-revenue-of-107_2m-beats-0_53m • Accuray press release (NASDAQ:ARAY): Q2 GAAP EPS of -$0.10 misses by $0.05. • Revenue of $107.2M (-6.6% Y/Y) beats by $0.53M. • The company is reaffirming guidance for fiscal year 2024 as follows: • Total revenue is expected in the range of $460 million to $470 million, vs. consensus of $463.17M, representing a year-over-year growth range of 3 to 5 percent. • Adjusted EBITDA for fiscal year 2024 is expected in the range of $27 million to $30 million.